Results 1 to 10 of about 1,578,579 (98)

<i>In vitro</i> potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb. [PDF]

J Allergy Clin Immunol Glob
Background: IL-13 plays a key role in the induction and perpetuation of type 2 immune responses associated with the development of atopic dermatitis and other chronic inflammatory diseases.
Zhu E, Prentice H, Oh J, Shaheen H, Gandhi NA, Wickman G, Dabora R, Dambkowski CL, Dillinger L.   +8 more
europepmc   +2 more sources

Dupilumab attenuate IL-4 and IL-13 synergistic effect on airway remodeling in asthma via blocking IL-4Rα/STAT6 axis. [PDF]

Sci Rep
Airway fibrosis in severe asthma is a hallmark of disease pathology, yet the mechanisms driving fibroblast activation remain incompletely understood. While interleukin-4 (IL-4) and interleukin-13 (IL-13) are central to type 2 inflammation, their combined
Sahnoon L, Abujabal R, Alanta TM, Mdkhana B, Olivenstein R, Puré E, Mahboub B, Laumonnier Y, Hamoudi R, Bajbouj K, Hamid Q.   +10 more
europepmc   +2 more sources

IL-13Rα2 Regulates the IL-13/IFN-γ Balance during Innate Lymphoid Cell and Dendritic Cell Responses to Pox Viral Vector-Based Vaccination

Vaccines, 2021
We have shown that manipulation of IL-13 and STAT6 signaling at the vaccination site can lead to different innate lymphoid cell (ILC)/dendritic cell (DC) recruitment, resulting in high avidity/poly-functional T cells and effective antibody ...
Zheyi Li, Sreeja Roy, Charani Ranasinghe
doaj   +1 more source

The Diagnostic Utility of Interleukin-13 and Interleukin-17A using the ELISA Technique in Asthmatic Children

Journal of Pure and Applied Microbiology, 2022
The heterogeneous etiology of asthma makes its diagnosis complicated. Measurement of cytokine levels could be relevant in determining the asthma phenotype, predicting severity, and identifying the treatment type. Enzyme-linked immunosorbent assay (ELISA)
Sawsan M. Jabbar AL-Hasnawi, Dhiaa H. Jawad Al-khayat   +1 more
doaj   +1 more source

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13

Vaccines, 2022
Interleukin-4 (IL-4) and interleukin-13 (IL-13) are key cytokines involved in the pathophysiology of both immune-inflammatory and structural changes underlying type 2 asthma.
Corrado Pelaia, Giulia Pelaia, Claudia Crimi, Angelantonio Maglio, Giuseppe Armentaro, Cecilia Calabrese, Angela Sciacqua, Luca Gallelli, Alessandro Vatrella   +8 more
doaj   +1 more source

Effect of Agmatine on a mouse model of allergic airway inflammation: A comparative study

Autoimmunity, 2022
Introduction Asthma is a chronic lung disease that injures and constricts the airways. This study evaluates the effects of agmatine on ovalbumin (OVA)-induced allergic inflammation of the airways.
Mohammed K. Еlmahdy, Rania R. Abdelaziz, Hoda S. Elmahdi, Ghada M. Suddеk   +3 more
doaj   +1 more source

A Case of Papuloerythroderma Successfully Treated with Dupilumab

Case Reports in Dermatology, 2022
Papuloerythroderma is an erythroderma characterized by the composition of dense paving stone shape papules and intertriginous uninvolved skin on the abdominal wall and is often intractable and accompanied by itching.
Ayaka Mizuno, Koji Habe, Yoshiaki Matsushima, Makoto Kondo, Keiichi Yamanaka   +4 more
doaj   +1 more source

IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma [PDF]

PeerJ, 2022
Allergic rhinitis (AR) is a common disorder of the upper airway, while asthma is a disease affecting the lower airway and both diseases are usually comorbid.
Siti Muhamad Nur Husna, Norasnieda Md Shukri, Noor Suryani Mohd Ashari, Kah Keng Wong   +3 more
doaj   +2 more sources

Assessment of the rapid effect of dupilumab in two cases of severe asthma comorbid with recurrent eosinophilic chronic rhinosinusitis after endoscopic sinus surgery

Respirology Case Reports, 2021
Dupilumab, a human monoclonal antibody against interleukin‐4 (IL‐4) and IL‐13, has been approved for treating severe asthma and eosinophilic chronic rhinosinusitis (ECRS).
Yoshiro Kai, Masanori Yoshikawa, Masayuki Matsuda, Atsuhiko Fukuoka, Yukio Fujita, Motoo Yamauchi, Shigeo Muro   +6 more
doaj   +1 more source

Impact of Anti-Diabetic Treatments on Circulating Anti-Inflammatory Mediators (IL-10 and IL-13) in Type 2 Diabetes Patients [PDF]

Journal of Bioscience and Applied Research
Background and Objectives: Type 2 diabetes mellitus (T2DM) is a chronic condition marked by persistent hyperglycemia and low-grade inflammation, involving cytokines like IL-10 and IL-13.
Muhannad Shweash, Hatem Hadeed, Mahmood Mukhlif, Mohammed Shwaish, Haitham Abd   +4 more
doaj   +1 more source